Literature DB >> 15610097

Variation in patterns of practice in diagnosing screen-detected prostate cancer.

Robert K Nam1, Ants Toi, John Trachtenberg, Michael A S Jewett, Laurence Klotz, Neil Fleshner, P Scott Bagnell, Joan Sweet, Linda Sugar, Steven A Narod.   

Abstract

OBJECTIVE: To determine the practice pattern of repeat prostate biopsies to detect prostate cancer, as there is growing evidence to support the recommendation that a repeat prostate biopsy should be taken after an initially negative prostate biopsy, the rate of cancer detection then being approximately 30%. PATIENTS AND METHODS: We examined the practice patterns of taking a repeat prostate biopsy after an initial negative biopsy and the predictors for cancer at repeat biopsy among 1536 patients who had an initial prostate biopsy because of an elevated prostate-specific antigen (PSA) level (>4.0 ng/mL) or abnormal digital rectal examination.
RESULTS: Of the 1536 men, 712 (46.4%) had cancer detected on the first biopsy; of the remaining 824 with no cancer detected, 268 (32.5%) had a repeat biopsy within a year, and 68 of these (25.4%) had cancer detected. Of the cancers detected at repeat biopsy, 31% were high-grade. Men with abnormal histology (prostatic intraepithelial neoplasia or atypia) had an odds ratio of 3.2 (P < 0.001) for having a repeat biopsy. For men with normal initial prostate histology, those with an initial PSA of 10.0-20.0 and >20.0 ng/mL had an odds ratio of 3.6 and 4.5 (both P < 0.001), respectively, for a repeat prostate biopsy, compared with patients with a PSA of <10.0 ng/mL. However, the PSA level was not predictive of prostate cancer at repeat biopsy, but age and prostate volume were.
CONCLUSIONS: A third of patients had a repeat biopsy after a negative biopsy. The most important factors influencing whether a patient was to have a repeat biopsy were initial biopsy histology and PSA level. However, the latter was not an important factor for predicting prostate cancer at repeat biopsy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15610097     DOI: 10.1111/j.1464-410X.2004.05150.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  2 in total

1.  New variants at 10q26 and 15q21 are associated with aggressive prostate cancer in a genome-wide association study from a prostate biopsy screening cohort.

Authors:  Robert K Nam; William Zhang; Katherine Siminovitch; Adam Shlien; Michael W Kattan; Laurence H Klotz; John Trachtenberg; Yan Lu; Jinyi Zhang; Changhong Yu; Ants Toi; D Andrew Loblaw; Vasundara Venkateswaran; Aleksandra Stanimirovic; Linda Sugar; David Malkin; Arun Seth; Steven A Narod
Journal:  Cancer Biol Ther       Date:  2011-12-01       Impact factor: 4.742

Review 2.  Dealing with non-cancerous findings on prostate biopsy.

Authors:  Timothy C Brand; Gregory P Thibault; Joseph W Basler
Journal:  Curr Urol Rep       Date:  2006-05       Impact factor: 2.862

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.